Source: Blackrock Neurotech and the Utah Array
source confidence: Medium status: Useful updated 2026-05-09
Summary
Industry-press coverage of Blackrock Neurotech's Utah Electrode Array, including its development history at the University of Utah, current clinical use, FDA Breakthrough Device designation for the MoveAgain motor BCI system, and the next-generation Neuralace flexible-mesh device.
Useful Claims
- The Utah Array gathers neural signals across up to 96–100 electrode channels per device.
- Public coverage describes more than 30,000 cumulative patient-days of human implantation across paralysis and ALS studies.
- This capture does not establish the reported claim that MoveAgain has FDA Breakthrough Device designation; it mentions neither MoveAgain nor the designation.
- Neuralace is described in public coverage as a flexible array with more than 10,000 channels.
Verbatim
"The array gathers neural signals from up to 100 channels per device, and it’s the only BCI implant with documented long-term stability and safety in humans. It has been studied in dozens of patients for a total of more than 30,000 days, demonstrating groundbreaking performance." — Article body, "What is the Utah Array?"
"Some use cases do require higher channel count, such as applications for memory and vision. For these applications, Blackrock has developed novel electrodes with 10,000 channels and beyond." — Article body, "Advantages, challenges and opportunities"
Reliability Notes
The capture does not substantiate MoveAgain's Breakthrough Device designation; that requires separate regulatory sources.
Reasonable secondary source for the company's public technical positioning. Not a primary clinical evidence source. Some claim language echoes Blackrock marketing materials and should be triangulated against peer-reviewed publications and FDA documents before being relied on for clinical assertions.